EAM
RLMD icon

Eventide Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Eventide Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
1,858,416
+1,016,310
+121% +$7.1M 0.17% 140
2026
Q1 		$5.86M Buy
+842,106
New +$3.98M 0.1% 154

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eventide Asset Management's RLMD Position: Q2 2026 in Review

Eventide Asset Management increased its Relmada Therapeutics (RLMD) stake by 121% in Q2 2026, buying an estimated $7.1M and bringing the position to 1,858,416 shares worth $12.9M. The position accounts for 0.17% of the portfolio, ranked #140.

Eventide Asset Management first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Eventide Asset Management held 1,858,416 shares of Relmada Therapeutics worth $12.9M as of Q2 2026.
  • Eventide Asset Management bought 1,016,310 Relmada Therapeutics shares in Q2 2026, an estimated $7.1M.
  • Relmada Therapeutics made up 0.17% of Eventide Asset Management's portfolio in Q2 2026, its #140 holding.
  • Eventide Asset Management first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.